Angitia Biopharmaceuticals

At Angitia Biopharmaceuticals, we are at the vanguard of biotechnological innovation, dedicated to pioneering and advancing breakthrough therapeutics for severe musculoskeletal diseases. Established in 2018, our focus is on addressing significant unmet medical needs by leveraging our team's profound scientific expertise and extensive experience in the development of novel drugs. Through groundbreaking research and a commitment to scientific rigor, we are revolutionizing the treatment landscape for conditions such as osteoporosis, osteogenesis imperfecta (OI), and degenerative disc disease. Our pipeline is a testament to our innovative approach, featuring biologic product candidates like AGA111, a recombinant human bone morphogenetic protein 6 (rhBMP6) for spinal fusion, and bispecific antibodies such as AGA2118 and AGA2115, which target sclerostin and DKK1 to promote bone health. These cutting-edge therapies are designed to not only treat symptoms but to fundamentally alter the course of debilitating diseases, offering new hope to patients worldwide.

Our commitment to innovation is matched by our dedication to our global team and the patients we serve. Angitia fosters a culture of respect, equality, and continuous growth, believing that a diverse and empowered team is the cornerstone of our success. We are advancing our clinical programs with a sense of urgency and purpose, with multiple candidates in various stages of clinical trials. The recent progress of AGA111 into a Phase 3 registrational study and the promising data from our Phase 1/2 trials underscore our capability to translate complex science into tangible clinical outcomes. By forging strong collaborations with academic institutions and global biopharmaceutical partners, we are accelerating the development of our innovative pipeline. Angitia Biopharmaceuticals is not just developing medicines; we are engineering a future where patients with serious musculoskeletal disorders can lead healthier, more active lives, driven by the relentless pursuit of scientific excellence and patient-centered innovation.